Aurinia Pharmaceuticals (AUPH) Projected to Post Earnings on Thursday

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) is projected to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Aurinia Pharmaceuticals to post earnings of $0.21 per share for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Aurinia Pharmaceuticals Price Performance

Aurinia Pharmaceuticals stock opened at $14.59 on Wednesday. The company has a current ratio of 5.76, a quick ratio of 5.17 and a debt-to-equity ratio of 0.15. The company has a fifty day simple moving average of $15.07 and a 200-day simple moving average of $13.88. The stock has a market cap of $1.92 billion, a P/E ratio of 26.05 and a beta of 1.50. Aurinia Pharmaceuticals has a 12-month low of $6.55 and a 12-month high of $16.54.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Arrowstreet Capital Limited Partnership increased its holdings in shares of Aurinia Pharmaceuticals by 0.4% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 3,387,194 shares of the biotechnology company’s stock valued at $54,026,000 after acquiring an additional 13,173 shares during the period. Renaissance Technologies LLC grew its position in Aurinia Pharmaceuticals by 9.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,590,135 shares of the biotechnology company’s stock worth $25,363,000 after purchasing an additional 140,535 shares during the last quarter. Marshall Wace LLP increased its stake in Aurinia Pharmaceuticals by 6.2% in the fourth quarter. Marshall Wace LLP now owns 1,574,957 shares of the biotechnology company’s stock valued at $25,121,000 after purchasing an additional 91,825 shares during the period. Geode Capital Management LLC raised its holdings in shares of Aurinia Pharmaceuticals by 1.5% in the fourth quarter. Geode Capital Management LLC now owns 1,507,869 shares of the biotechnology company’s stock valued at $24,047,000 after buying an additional 22,169 shares during the last quarter. Finally, Two Sigma Investments LP raised its holdings in shares of Aurinia Pharmaceuticals by 728.6% in the third quarter. Two Sigma Investments LP now owns 1,341,067 shares of the biotechnology company’s stock valued at $14,819,000 after buying an additional 1,179,219 shares during the last quarter. 36.83% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

AUPH has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, January 21st. Bloom Burton lowered Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, November 5th. Jefferies Financial Group raised Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and upped their price target for the company from $10.00 to $21.00 in a report on Friday, November 7th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $15.00 price target (up from $9.00) on shares of Aurinia Pharmaceuticals in a research note on Wednesday, November 5th. Finally, Leerink Partners cut shares of Aurinia Pharmaceuticals from an “outperform” rating to a “market perform” rating and raised their price objective for the stock from $15.00 to $16.00 in a report on Wednesday, December 3rd. Two research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $17.25.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.